Ann Arbor-based Aastrom Biosciences Inc. received "orphan drug" status
from the FDA for its tissue repair cells developed for a chronic heart
condition.
Excerpt:
FDA orphan drug designation provides a variety of incentives for companies to produce treatments for comparatively rare diseases, including seven years of market exclusivity and expedited product review, and a chance at reduced filing FDA fees and tax credits.
Read the entire article
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.